A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
NCT06976268
This study is recruiting at 24 US sites in 16 states, according to its ClinicalTrials.gov record last updated .
Summary
A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease. The study will consist of a 48-week double-blind treatment phase followed by a 48-week open-label phase.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Parkinson Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2/3
- Ages
- 40 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Biohaven Therapeutics Ltd.
- Last updated on ClinicalTrials.gov
- September 28, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- Site-049 · Birmingham, AL
California · 2
- Site-003 · Irvine, CA
- Site-041 · Los Angeles, CA
Colorado · 1
- Site-025 · Aurora, CO
Connecticut · 2
- Site-031 · Farmington, CT
- Site-028 · New Haven, CT
Florida · 3
- Site-038 · Atlantis, FL
- Site-017 · Boca Raton, FL
- Site-051 · Maitland, FL
Illinois · 1
- Site-027 · Chicago, IL
Kansas · 1
- Site-029 · Kansas City, KS
Massachusetts · 2
- Site-071 · Boston, MA
- Site-004 · Foxborough, MA
Michigan · 1
- Site-015 · Farmington Hills, MI
Missouri · 1
- Site-044 · Chesterfield, MO
New York · 2
- Site-006 · Albany, NY
- Site-005 · New York, NY
Ohio · 1
- Site-082 · Cleveland, OH
Oregon · 1
- Site-091 · Portland, OR
Texas · 1
- Site-043 · Round Rock, TX
Virginia · 2
- Site-009 · Henrico, VA
- Site-074 · Newport News, VA
Washington · 2
- Site-007 · Bellevue, WA
- Site-019 · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.